Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
Japan Tobacco on November 29 submitted a new drug application in Japan for its renal anemia treatment enarodustat, making it the fourth drug in a class of medicines called HIF-PH inhibitors to be filed in the country, the company and…
To read the full story
Related Article
- JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
July 16, 2019
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
BUSINESS
- Lilly, Tanabe Signal Supply Restrictions over Suspected Mounjaro Misuse
November 9, 2026
- Celltrion to Lift Shipment Curbs on Japan’s 1st Actemra Biosimilar
November 9, 2026
- AstraZeneca Vows to Back Japanese Innovation with Global Potential
November 9, 2026
- Nippon Shinyaku Flags Possible IR Data Leak
November 9, 2026
- Espha Debuts NorLevo Generic in Japan
November 9, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…